Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis

We found that glargine once daily, detemir once daily, and detemir twice daily significantly reduced HbA1c compared with NPH once daily in our network meta-analysis. Given the small reduction in hemoglobin HbA1c observed, no differences are likely to be clinically relevant because they did not approach the commonly accepted 0.5% minimal clinically important difference in hemoglobin HbA1c (BMJ)